Vilanterol: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Vilanterol. Educational only — not medical advice.
Labeled uses
Umeclidinium and Vilanterol ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use Umeclidinium and Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of Umeclidinium and Vilanterol ELLIPTA in asthma have not been established.
Source: FDA labeling via NIH DailyMed (set 6de414b1…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.